Страна: САЩ
Език: английски
Източник: NLM (National Library of Medicine)
Docetaxel Anhydrous (UNII: 699121PHCA) (Docetaxel Anhydrous - UNII:699121PHCA)
Sagent Pharmaceuticals
Docetaxel Anhydrous
Docetaxel Anhydrous 20 mg in 1 mL
INTRAVENOUS
PRESCRIPTION DRUG
Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced ga
One-vial Formulation Docetaxel Injection, USP is available as a nonaqueous solution as follows: Docetaxel Injection, USP 20 mg per 1 mL: 20 mg docetaxel in 1 mL 50/50 (v/v) ratio polysorbate 80/dehydrated alcohol. The vial is in a blister pack in one carton. Docetaxel Injection, USP 80 mg per 4 mL: 80 mg docetaxel in 4 mL 50/50 (v/v) ratio polysorbate 80/dehydrated alcohol. The vial is in a blister pack in one carton. Store between 2° and 25°C (36° and 77°F). Freezing does not adversely affect the product. Protect from light. Retain in carton until time of use. Docetaxel Injection, USP is a hazardous drug. Follow applicable special handling and disposal procedures. Discard unused portion. Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex.
Abbreviated New Drug Application
DOCETAXEL- DOCETAXEL ANHYDROUS INJECTION, SOLUTION SAGENT PHARMACEUTICALS ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE DOCETAXEL INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR DOCETAXEL INJECTION. DOCETAXEL INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 1996 WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, AND FLUID RETENTION _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ TREATMENT-RELATED MORTALITY INCREASES WITH ABNORMAL LIVER FUNCTION, AT HIGHER DOSES, AND IN PATIENTS WITH NSCLC AND PRIOR PLATINUM-BASED THERAPY RECEIVING DOCETAXEL AT 100 MG/M (5.1) AVOID USE OF DOCETAXEL IF BILIRUBIN > ULN, OR IF AST AND/OR ALT >1.5 X ULN CONCOMITANT WITH ALKALINE PHOSPHATASE >2.5 X ULN. LFT ELEVATIONS INCREASE RISK OF SEVERE OR LIFE-THREATENING COMPLICATIONS. OBTAIN LFTS BEFORE EACH TREATMENT CYCLE (5.2) DO NOT ADMINISTER DOCETAXEL TO PATIENTS WITH NEUTROPHIL COUNTS <1500 CELLS/MM . OBTAIN FREQUENT BLOOD COUNTS TO MONITOR FOR NEUTROPENIA (4, 5.3) SEVERE HYPERSENSITIVITY, INCLUDING FATAL ANAPHYLAXIS, HAS BEEN REPORTED IN PATIENTS WHO RECEIVED DEXAMETHASONE PREMEDICATION. SEVERE REACTIONS REQUIRE IMMEDIATE DISCONTINUATION OF DOCETAXEL AND ADMINISTRATION OF APPROPRIATE THERAPY (5.5) CONTRAINDICATED IF HISTORY OF SEVERE HYPERSENSITIVITY REACTIONS TO DOCETAXEL OR TO DRUGS FORMULATED WITH POLYSORBATE 80 (4) SEVERE FLUID RETENTION MAY OCCUR DESPITE DEXAMETHASONE (5.6) INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: BREAST CANCER (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC (1.1) NON-SMALL CELL LUNG CANCER (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC (1.2) CASTRATION-RESISTANT PROSTATE CANCE Прочетете целия документ